Skip to main content
OpenTrials
Completed

NCT Number: NCT02926456

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)

The purpose of this study is to describe the effectiveness of darunavir/cobicistat (DRV/c)-based regimens, measured as maintenance of virological suppression 48 weeks after baseline, defined as the day when the treatment with DRV/c-based regimen is started, through collection of daily practice data in the Italian setting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Immunodeficiency Virus Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult greater than or equal to (>=18 years), male and female patients
  • Documented Human Immunodeficiency Virus-1 (HIV-1) infection
  • Eligible to darunavir/cobicistat (DRV/c) treatment according to Summary of Product Characteristics
  • Patients who are able to understand the nature of the study and to provide their consent voluntarily having signed an Informed Consent Form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Patients in stable (>= 12 months) treatment with an Antiretroviral (ARV) therapy PI/ritonavir (PI/r)-based, being prescribed Rezolsta (DRV/c) by treating physician
  • Patients virosuppressed (HIV-RNA less than [<] 50 copies/milliliters) since at least 6 months, within their HIV treatment at the moment of enrollment; single values of HIV-RNA more than [>] 50 copies/ml not confirmed (blips) will be considered acceptable; last value collected being < 50 copies/ml

Exclusion criteria

  • Patient currently enrolled in an interventional study
  • Patient currently enrolled in an observational study sponsored or supported by Janssen
  • Estimated Glomerular Filtration Rate (eGFR) < 70 milliliters per minute (ml/min) if any co-administered agent (example emtricitabine, lamivudine, tenofovir disoproxil fumarate, or adefovir dipivoxil) requires dose adjustment based on creatinine clearance
  • Pregnancy or breast feeding at enrollment
  • Allergy or intolerance to sulphonamides
  • Switch from darunavir/ritonavir (DRV/r) 600/100 bis in die (bid)
  • Patient currently in mono PI/r therapy
  • Patients to be treated within one year with Direct Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) infection
  • Chemotherapy scheduled

Treatment and study plan

Primary outcomes

  1. Percentage of Patients With Human Immunodeficiency Virus - RiboNucleic Acid (HIV-RNA) Less Than (<)50 Copies/Milliliters (copies/mL) Measured at Week 48

    Time frame: At Visit 4 (Week 48)

    The percentage of patients with plasma HIV-RNA<50 copies/mL will be analyzed by FDA snapshot analysis (FDA Snapshot Approach is based on the last observed viral load data within the Week 48 window: virologic response is defined as HIV-1 RNA <50 copies/mL (observed case); If there are no data in the defined time window, the proportion of missing data and relative reason will be provided") and Time to loss of virologic response (TLOVR) method algorithm requires sustained HIV-1 RNA < 50 copies/mL; confirmed HIV-1 RNA more than or equal to (>=) 50 copies/mL is considered as non-response (rebound); patients considered non-responder after permanent discontinuation).

Secondary outcomes

  1. Change From Baseline in HIV-Symptoms Distress Module (HIV-SDM) Score

    Time frame: Baseline, Up to Visit 4 (Week 48)

    HIV-SDM is a questionnaire consisting of 20 questions related to all the symptoms which the patient might have had during the past four weeks. For each question patient has to select appropriate answer related to the symptoms: "0 = I do not have this symptom; 1 = I have this symptom and it doesn't bother me; 2 = it bothers me a little; 3 = it bothers me; 4 = it bothers me a lot".

  2. Change From Baseline in HIV-Treatment Satisfaction Questionnaire (HIV-TSQ) Score

    Time frame: Baseline, Up to Visit 4 (Week 48)

    The HIV Treatment Satisfaction Questionnaire (HIV-TSQ) is a 10-item instrument that is supported by evidence of good internal consistency reliability. The total score ranges from 0 to 60, with higher scores indicating greater treatment satisfaction. Score change ranges from -30 to +30, with scores<0 and >0 indicating a decrease and increase in treatment satisfaction, respectively.

  3. Percentage of Patients with HIV-RNA <50 copies/mL Measured at Week 24

    Time frame: At Visit 3 (Week 24)

  4. Change From Baseline in CD4 Cell Count

    Time frame: Baseline, Up to Visit 4 (Week 48)

    CD4 cell count will be assessed as immunological parameter.

  5. Change From Baseline in CD4/CD8 Ratio

    Time frame: Baseline, Up to Visit 4 (Week 48)

    CD4/CD8 ratio will be assessed as immunological parameter.

  6. Change From Baseline in CD4 Percentage

    Time frame: Baseline, Up to Visit 4 (Week 48)

    CD4 percentage will be assessed as immunological parameter.

  7. Change From Baseline in Creatinine Levels

    Time frame: Baseline, Up to Visit 4 (Week 48)

    The change from baseline in serum creatinine up to 48 weeks will be assessed.

  8. Change From Baseline in estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, Up to Visit 4 (Week 48)

    The change from baseline in eGFR will be assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

  9. Change From Baseline in Aspartate Transferase (AST)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  10. Change From Baseline in Alanine-Amino Transferase (ALT)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  11. Change From Baseline in Gamma-Glutamyl Transferase (GGT)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  12. Change From Baseline in Alkaline Phosphatase (ALP)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  13. Change From Baseline in Total Cholesterol

    Time frame: Baseline, Up to Visit 4 (Week 48)

  14. Change From Baseline in Low Density Lypoprotein (LDL)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  15. Change From Baseline in High Density Lypoprotein (HDL)

    Time frame: Baseline, Up to Visit 4 (Week 48)

  16. Change From Baseline in Triglycerides

    Time frame: Baseline, Up to Visit 4 (Week 48)

  17. Change From Baseline in Glucose

    Time frame: Baseline, Up to Visit 4 (Week 48)

Sponsors and collaborators

Lead sponsor

Janssen-Cilag S.p.A.

Industry

Registry information

Official study title

Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study

Acronym: STORE

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Oct 6, 2016
Registry last updated
Apr 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.